Both doses of Trastuzumab duocarmazine (SYD985) (3 mg/kg or 10 mg/kg, i.v., once) significantly inhibit tumor growth and prolong the survival of mice, demonstrating potent in vivo anti-tumor activity [1].
In Vitro
Trastuzumab duocarmazine (SYD985) exhibits cytotoxic activity against both HER2-negative and HER2-positive cells, with an IC50 range of 0.0001-100 μg/mL after 24 hours of treatment. In comparison to T-DM1 with an IC50 value of 0.096 μg/mL, its cytotoxicity is 7 times higher against HER2/NEU3+ cell lines, with an IC50 value of 0.013 μg/mL. Importantly, in HER2/NEU1+ cells, its cytotoxicity is 54 times higher than that of T-DM1 [1].
Kinase Assay
Cell Assay
Animal Administration
References
[1]. Gulden Menderes, et al. SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression. Clin Cancer Res. 2017 Oct 1;23(19):5836-5845.
Return Policy
If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.
Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.
